J. Avorn and W. Shrank, Highlights and a Hidden Hazard ??? The FDA's New Labeling Regulations, New England Journal of Medicine, vol.354, issue.23, pp.2409-2411, 2006.
DOI : 10.1056/NEJMp068119

D. Patrick, L. Burke, and C. Gwaltney, Content Validity???Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1???Eliciting Concepts for a New PRO Instrument, Value in Health, vol.14, issue.8, pp.967-977, 2011.
DOI : 10.1016/j.jval.2011.06.014

A. Gnanasakthy, M. Mordin, and M. Clark, A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010, Value in Health, vol.15, issue.3, pp.437-442, 2012.
DOI : 10.1016/j.jval.2011.11.032

I. Guidance, Patient-reported outcome measures: use in medical product development to support labeling claims US food and drug administration

. Rockville, MD: U.S. Food and Drug Administration, 2009.

G. Provost, Homeless " or " orphan " drugs, Am J Hosp Pharm, vol.25, p.609, 1968.

M. Brundage, B. Bass, and J. Davidson, Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers, Quality of Life Research, vol.41, issue.12, pp.653-664, 2011.
DOI : 10.1016/j.ejca.2005.05.007

A. Gnanasakthy, M. Mordin, and E. Haydysch, FDA patient-reported outcome labeling of novel therapies (2011-2015) Value in Health, pp.285-86, 2016.

M. Clark, C. Simons, and E. Haydysch, A Review Of Patient-Reported Outcome Orphan Drug Labels In The United States From January 2006-September 2013: Analysis Of Evidence For Orphan Drug Pro Label Claims, Value in Health, vol.17, issue.3, p.166, 2006.
DOI : 10.1016/j.jval.2014.03.964

E. Basch and A. Bennett, Patient-Reported Outcomes in Clinical Trials of Rare Diseases, Journal of General Internal Medicine, vol.16, issue.5, pp.801-804, 2014.
DOI : 10.1016/j.jval.2013.04.004

N. Leidy, Addressing content validity of PRO measures: the unique case of rare diseases In: EveryLife foundation, workshop 2: clinical evaluation of rare disease treatments, EveryLife Foundation for Rare Diseases, 2011.

. Adempas, Highlights of prescribing information.: U.S. Food and Drug Administration (FDA), 2013.